Skip to main content
Elsevier

Cancer Treatment and the Ovary

Clinical and Laboratory Analysis of Ovarian Toxicity

  • 1st Edition - July 28, 2015
  • Latest edition
  • Editors: Richard A Anderson, Norah Spears
  • Language: English

Cancer Treatment and the Ovary: Clinical and Laboratory Analysis of Ovarian Toxicity provides the reader with a basic understanding on how the ovary is adversely impacted… Read more

End of Summer Sale

Save up to 30% off

Bright savings for research, study, and discovery

Shop the summer sale

Description

Cancer Treatment and the Ovary: Clinical and Laboratory Analysis of Ovarian Toxicity

provides the reader with a basic understanding on how the ovary is adversely impacted by cancer treatment, an essential foundational knowledge for this rapidly-developing field.

The book describes both the clinical and laboratory approaches to discovering the potentially adverse effects of cancer treatment on the ovary, also laying out possible preventative approaches and future directions for the field.

Clinicians working in the field of reproductive biology and oncology will find an essential reference that provides the necessary tools to assess the reproductive toxicological effects of cancer treatments.

Key features

  • Brings together an international group of experts to address the current state of the science of ovarian toxicity caused by cancer treatment
  • Provides scientific, clinical, and preclinical approaches to assessing this toxicity
  • Describes current techniques and future strategies to protect the ovary
  • Ideal reference for the further study of ovarian toxicity, oncofertility, cancer treatment, and reproductive toxicology

Readership

Professionals working in the assessment of reproductive toxicological effects of cancer treatments and clinicians working in the fields of reproductive biology and oncology.

Table of contents

  • List of Contributors
  • Foreword
  • Introduction
  • Section I: Clinical
    • Chapter 1. Ovarian Follicle Biology and the Basis for Gonadotoxicity
      • 1.1 Overview of Ovarian Function
      • 1.2 Ovarian Development
      • 1.3 Molecular Mechanisms Controlling Primordial Follicle Activation
      • 1.4 Local Control of Early Follicle Development
      • 1.5 Endocrine Control of Later Follicle Development
      • 1.6 Reproductive Lifespan and the Ovarian Primordial Follicle Reserve
      • 1.7 Germ Cell Sensitivity to Cell Death
      • 1.8 Conclusion
      • References
    • Chapter 2. Relevant Cancer Diagnoses, Commonly Used Chemotherapy Agents and Their Biochemical Mechanisms of Action
      • 2.1 Introduction
      • 2.2 Impact of Radiotherapy on Future Female Fertility
      • 2.3 Impact of Chemotherapy on Future Female Fertility
      • 2.4 Mechanisms of Action of the Commonly Used Chemotherapy Drugs
      • References
    • Chapter 3. Clinical Assessment of Ovarian Toxicity
      • 3.1 Introduction
      • 3.2 The Use of Chemotherapy-Related Amenorrhoea
      • 3.3 Biomarkers of the Ovarian Reserve
      • 3.4 AMH and Determination of Gonadotoxicity
      • 3.5 Conclusion
      • Acknowledgement
      • References
    • Chapter 4. The Current Understanding of Clinical Data on Ovarian Toxicity from Cancer Treatment
      • 4.1 Introduction
      • 4.2 Risk Factors for Premature Ovarian Insufficiency After Chemotherapy
      • 4.3 How do Chemotherapeutics Damage the Ovary?
      • 4.4 The Relevance of BRCA Mutations to Ovarian Damage after Chemotherapy
      • 4.5 Conclusion
      • References
  • Section II: Laboratory Models
    • Chapter 5. In Vivo Models of Ovarian Toxicity
      • 5.1 Introduction
      • 5.2 Rodent Models of Chemotherapy-Induced Follicular Depletion and Ovoprotection
      • 5.3 Primate Models of Chemotherapy-Induced Ovarian Toxicity and Ovoprotection
      • 5.4 Conclusion
      • References
    • Chapter 6. In Vitro Models of Ovarian Toxicity
      • 6.1 Introduction
      • 6.2 Why Use Culture Systems?
      • 6.3 What Culture Systems are Available?
      • 6.4 Human and other Primate Model Studies of Ovarian Chemotherapy Toxicity
      • 6.5 Rodent Model Studies of Ovarian Chemotherapy Toxicity
      • 6.6 Ovarian Cell Culture Techniques in Chemotherapy Studies
      • 6.7 Conclusion
      • References
  • Section III: Strategies to Protect the Ovary
    • Chapter 7. Ovarian Tissue Cryopreservation for Fertility Preservation
      • 7.1 Overview
      • 7.2 Ovarian Tissue Cryopreservation
      • 7.3 Transplantation of Cryopreserved Ovarian Tissue
      • 7.4 Outcome of Transplantations
      • 7.5 Longevity of Grafts
      • 7.6 Risk of Re-Implanting Malignant Cells
      • 7.7 Conclusion
      • References
    • Chapter 8. Current Clinical Approaches to Protecting the Ovary: GnRH Analogues
      • 8.1 Introduction
      • 8.2 Distribution and Roles of the GnRH/GnRH Receptor System
      • 8.3 GnRH Agonists
      • 8.4 GnRH Agonist Co-treatment with Chemotherapy for the Protection of the Ovary
      • 8.5 Suggested Mechanisms of Gonadotoxic Protection by GnRH Agonists
      • 8.6 Conclusion
      • References
    • Chapter 9. Preclinical Approaches to the Protection of Ovarian Function
      • 9.1 Introduction
      • 9.2 Ovarian Protection by Affecting Apoptotic Pathways
      • 9.3 PI3K Follicle Activation Pathway and Ovary Protection
      • 9.4 Other Potential Methods of Reducing Chemotherapy-Induced Ovotoxicity
      • 9.5 Conclusion
      • References

Product details

  • Edition: 1
  • Latest edition
  • Published: July 28, 2015
  • Language: English

About the editors

RA

Richard A Anderson

Dr. Anderson's undergraduate training in medicine was punctuated by PhD in MRC Brain Metabolism Unit in neuroendocrinology with George Fink. He subsequently trained in Obstetrics and Gynaecology in Edinburgh, with interest in reproductive endocrinology fostered by WHO Research Fellow post in Hormonal Male Contraception. After completing subspecialty training in Reproductive Medicine as a lecturer with David Baird at the University of Edinburgh and a year in Sam Yen’s lab in San Diego he returned to the MRC Human Reproductive Sciences Unit in 1998 with a consultant post in Reproductive Endocrinology and Infertility at the Royal Infirmary of Edinburgh. Dr. Anderson was subsequently appointed to current post in the University in 2005. In recent years he has established a group investigating female reproductive lifespan, with laboratory and clinical aspects particularly related to the adverse effects of cancer treatment on fertility.
Affiliations and expertise
Professor of Clinical Reproductive Science, University of Edinburgh, UK

NS

Norah Spears

Dr. Spears studied for her BSc (Hons) at the University of Edinburgh, followed by a DPhil at Oxford University, supervised by John Clarke. After two years in Irv Zucker’s laboratory at the University of California at Berkeley, and a year in the Brain Metabolism Unit in Edinburgh, she moved to Physiology at the University of Edinburgh. She has worked there since 1990, using animal models to investigate reproductive physiology, holding an MRC Training Fellowship, followed by a Royal Society University Research Fellowship, until she took up a University position in the Centre for Integrative Physiology in 2002. Her current work investigates the effects of chemotherapy treatment on female and male gonads, using a variety of tissue culture techniques.
Affiliations and expertise
Centre for Integrative Physiology, University of Edinburgh, Edinburgh, UK

View book on ScienceDirect

Read Cancer Treatment and the Ovary on ScienceDirect